Streetbeat News

Analyst Ratings

HIMS

Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on Hims & Hers Health (NYSE:HIMS) and raised the price target from $12 to $14.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 3:40 pm

ATEN

Zacks Home Run Newsletter has reportedly purchased shares of A10 Networks (ATEN), a provider of secure application services for on-premises, multi-cloud, and edge-cloud environments.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 3:39 pm

AXP

Citigroup analyst Arren Cyganovich reiterated a Sell rating on American Express (NYSE:AXP) and lowered the price target from $150 to $148.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 3:19 pm

ALGT

In the last 3 months, 4 analysts have offered 12-month price targets for Allegiant Travel (NASDAQ:ALGT), with an average price target of $117.25. The average price target has increased by 11.67% over the past month.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:04 pm

ZS

In the last 3 months, 35 analysts have offered 12-month price targets for Zscaler (NASDAQ:ZS), with an average price target of $161.26, a high of $225.00, and a low of $120.00. The average price target has increased by 13.05% over the past month.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:03 pm

CRWD

In the last 3 months, 29 analysts have offered 12-month price targets for CrowdStrike Holdings (NASDAQ:CRWD), with an average price target of $177.55. The average price target has increased by 7.14% over the past month.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:02 pm

CYBR

Over the past 3 months, 15 analysts have published their opinion on CyberArk Software (NASDAQ:CYBR) stock, with an average price target of $179.33, implying an upside from the current price of $151.365. The current average has increased by 3.66% from the previous average price target of $173.00.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:02 pm

MIRM

Over the past 3 months, 5 analysts have published their opinion on Mirum Pharmaceuticals (NASDAQ:MIRM) stock, with all 5 giving bullish ratings. The company has an average 12-month price target of $65.0, representing a 21.69% decrease from the previous average price target of $83.00.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:01 pm

MSCI

11 analysts have provided ratings for MSCI (NYSE:MSCI) in the last quarter, with an average 12-month price target of $558.64, a decrease of 1.65% from the previous average of $568.00. The ratings include 7 somewhat bullish, 3 indifferent, and 1 somewhat bearish.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 3:01 pm

XOMA

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on XOMA (NASDAQ:XOMA) and maintains a $69 price target.

Portfolio Pulse from richadhand@benzinga.com

June 15, 2023 | 2:31 pm